Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Journal Information
Full Title: Leukemia
Abbreviation: Leukemia
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests This study was funded by Novartis Pharma GmbH. Medical writing was provided by Daniela Skalt, Stephanie Sussmann and Fabian Berkemeier. Statistical analyses were provided by Heidi Kulas and Guido Schiffhorst. These are employed by IGES Institut GmbH, which received financial support from Novartis Pharma GmbH for this research project. Katja Jäschke, Corinna Templin, Ulli Jeratsch and Daniela Kosmides are employees from Novartis GmbH and Etienne Jousseaume from Novartis Pharma AG which sponsored the studies ELIANA, ENSIGN and CCTL019B2001X."
"Funding Open Access funding enabled and organized by Projekt DEAL."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025